Clinical Trial Update: Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated trebananib in patients with advanced angiosarcoma unsuitable for surgical resection; the study has completed and results were poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angiosarcoma
• Soft Tissue Sarcoma

Drugs mentioned

• Trebananib (trebananib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Angiosarcoma, Recurrent Adult Soft Tissue Sarcoma | Phase 2 | Status: COMPLETED | Results posted: 2015-07-02